Cat allergy immunotherapy - Planet Biopharmaceuticals

Drug Profile

Cat allergy immunotherapy - Planet Biopharmaceuticals

Latest Information Update: 19 Feb 2014

Price : $50

At a glance

  • Originator Planet Biopharmaceuticals
  • Class Allergens; Antiallergics; Cat allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hypersensitivity

Most Recent Events

  • 19 Feb 2014 Discontinued - Phase-II for Hypersensitivity in USA (Sublingual)
  • 30 Nov 2011 No development reported - Phase-II for Hypersensitivity in USA (Sublingual)
  • 25 Nov 2009 Final efficacy & adverse events data from a phase II trial in Allergy released by Planet Biopharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top